Pulminiq delay
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Chiron anticipates a three-month delay in FDA's decision on its inhaled cyclosporine product Pulminiq because "FDA...has requested additional analysis of the pivotal study," the firm says Jan. 26. "As a result, the...action letter date will be extended to July," it notes. Chiron submitted an NDA for prevention of lung transplant rejection Oct. 14, 2004 (1Pharmaceutical Approvals Monthly Nov. 1, 2004, p. 29) and was granted a priority review...
You may also be interested in...
Chiron Submits Inhaled Immunosuppressant Pulminiq NDA For Lung Transplant
Chiron is requesting a priority review for its Pulminiq NDA, submitted October 14, which would place the user fee goal date for the aerosolized cyclosporine in April.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.